PROTEOMICS SHARED RESOURCE Director: Larry David, Ph.D. ABSTRACT/PROJECT SUMMARY The Knight Cancer Institute (Knight) sponsored Proteomics Shared Resource provides advanced tools and expertise in mass spectrometry to determine the identity, abundance, and modifications occurring in proteins. These analyses are crucial to understanding the cause of cancer and devising improved treatments for the disease. The resource supports a wide array of quantitative measurements including: detection of differential protein abundance in complex cell lysates derived from primary tumors, cell lines, cultured tumor organoids and patient-derived xenograft samples; detection of post-translation modifications, such as phosphorylation, acetylation, ubiquitination, methylation and O-GlycNAcylation, measurement of newly synthesized proteins; examination of protein/protein interactions; and, characterization of protein structure. The facility is a university- wide resource that leverages strong financial and administrative support from the institution to enhance cancer research across campus and sister institutions in a collaborative environment. It employs six highly trained individuals, five at the Ph.D. level, and maintains four mass spectrometer systems, one that is a state-of-the-art high-resolution Orbitrap Fusion instrument. Two of the staff provide full-time informatics support, which has a key role in the success of the facility. In addition, the Proteomics Shared Resource benefits from participation in the OHSU Pacific Northwest National Laboratory for Integrated Omics, which provides full access to expertise and instrumentation available through the NIGMS BioTechnology Research Resource in Proteomics at Pacific Northwest National Laboratory. Funds from this CCSG grant provide 10% salary support for the facility director, and 10% salary support for the associate director. The Proteomics Shared Resource will continue to work with the Knight and other OHSU stakeholders to identify and implement new technologies and assays that meet new research opportunities and evolving needs, including close collaboration with the Knight in providing tools and support needed by the new Knight early detection initiative.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-21
Application #
9733140
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259

Showing the most recent 10 out of 277 publications